A Clinical Trial to Investigate the Efficacy of BioCopper1®, Restore Cu1, and Grow + Restore Cu1 on Hair and Skin Improvements in Healthy Adults

The goal of this clinical trial is to investigate the efficacy of BioCopper1®, Restore Cu1, and Grow + Restore Cu1 on grey hair, hair growth, and/or skin improvements in healthy adults. The main question it aims to answer is: what is the change from baseline to Day 168 in percentage of grey hair between BioCopper1®, Restore Cu1, or Grow + Restore Cu1 and placebo, as assessed by HairMetrix? Researchers will compare the investigational products to a placebo to determine their effectiveness. Participants will be asked to: * Have their blood pressure, heart rate, height, and weight measurements taken * Have their blood samples collected * Complete questionnaires and a study diary * Be assessed using the VISIA imaging system, Corneometer, and Cutometer * Consume BioCopper1®, Restore Cu1, Grow + Restore Cu1, or placebo

Inclusion Criteria: 1. Males and females aged 18 to 45 years, inclusive 2. Stable body weight defined as a \2 times/week). Occasional users will be required to washout and abstain for the duration of the study period 25. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period 26. Alcohol intake average of \>2 standard drinks per day as assessed by the QI 27. Alcohol or drug abuse within the last 12 months 28. Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the efficacy and/or safety of the investigational product (Section 7.3) 29. Clinically significant abnormal laboratory results at screening as assessed by the QI 30. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit 31. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI 32. Individuals who are unable to give informed consent 33. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant